| [ Summary ] |
To reduce the incidence of cardiovascular disease, which accounts for half of the deaths in dialysis patients, the management of dyslipidemia is important. Dyslipidemia in dialysis patients is characterized by hypertriglyceridemia and hypo-HDL-cholesterolemia, with increased levels of VLDL and IDL, as well as a decreases levels of HDL. The guidelines of the Japan Atherosclerosis Society and the K/DOQI recommended that therapeutic lifestyle changes and lipid-lowering agents should be considered to reduce the levels of total cholesterol, LDL-C, TG and non-HDL-C to under 180mg/dl, less than 100mg/dl, less than 150 mg/l, and less than 130mg/l, respectively, while HDL-C should be increased to levels over 40mg/dl. |